@article{4b8658355ee44431a8f45e5c56d4b75a,
title = "Safety of Primary Thromboprophylaxis Using Apixaban in Ambulatory Cancer Patients with Intracranial Metastatic Disease or Primary Brain Tumors",
author = "S{\'e}bastien Miranda and Ygal Benhamou and Philip Wells and Marc Carrier",
note = "Funding Information: P.W. reports receiving grant support, lecture fees, and advisory board fees from Bayer HealthCare, lecture fees from Medscape, Pfizer, and Daiichi Sankyo, fees for serving on a writing committee from Itreas, grant support from Bristol-Myers Squibb/Pfizer, consulting fees from Janssen Scientific, and fees for serving on a roundtable from Sanofi. M.C. reports receiving grant support and honoraria from Leo Pharma and Bayer and honoraria from Sanofi-Aventis, Pfizer, and Bristol-Myers Squibb. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.",
year = "2019",
doi = "10.1055/s-0039-1695769",
language = "English",
volume = "119",
pages = "1886--1887",
journal = "Thrombosis and Haemostasis",
issn = "0340-6245",
publisher = "Georg Thieme Verlag",
number = "11",
}